TheStreet Lowers Oxford Immunotec Global PLC (OXFD) to Sell
Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research report issued on Monday.
Several other equities analysts have also recently weighed in on OXFD. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Oxford Immunotec Global PLC in a research note on Sunday, September 11th. Zacks Investment Research cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 5th.
Oxford Immunotec Global PLC (NASDAQ:OXFD) remained flat at $14.57 on Monday. 100,652 shares of the company were exchanged. The firm has a 50-day moving average of $13.51 and a 200 day moving average of $10.72. The firm’s market cap is $329.31 million. Oxford Immunotec Global PLC has a one year low of $7.73 and a one year high of $14.73.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, November 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.15. The firm had revenue of $26.10 million for the quarter, compared to the consensus estimate of $24.79 million. Oxford Immunotec Global PLC had a negative return on equity of 28.36% and a negative net margin of 30.17%. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.20) EPS. On average, analysts forecast that Oxford Immunotec Global PLC will post ($1.16) EPS for the current fiscal year.
In related news, Director Richard A. Sandberg sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $14.17, for a total value of $170,040.00. Following the completion of the sale, the director now owns 31,774 shares of the company’s stock, valued at approximately $450,237.58. The sale was disclosed in a document filed with the SEC, which is available at this link. 7.58% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in shares of Oxford Immunotec Global PLC during the third quarter valued at approximately $116,000. Prudential Financial Inc. purchased a new stake in shares of Oxford Immunotec Global PLC during the third quarter valued at approximately $139,000. SG Americas Securities LLC purchased a new stake in shares of Oxford Immunotec Global PLC during the second quarter valued at approximately $114,000. Societe Generale purchased a new stake in shares of Oxford Immunotec Global PLC during the second quarter valued at approximately $114,000. Finally, American International Group Inc. boosted its stake in shares of Oxford Immunotec Global PLC by 8.3% in the second quarter. American International Group Inc. now owns 12,779 shares of the company’s stock valued at $115,000 after buying an additional 982 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.